Main Menu

Publications Highlights View all by category

Types of Publications


Journal Articles

Sharp, S.Y., Boxall, K., Rowlands, M., Prodromou, C., Roe, S.M., Maloney, A., Powers, M., Clarke, P.A., Box, G., Sanderson, S., et al. (2019). Correction: In vitro Biological Characterization of a Novel, Synthetic Diaryl Pyrazole Resorcinol Class of Heat Shock Protein 90 Inhibitors. Cancer res, Vol.79 (1), pp. 287-287.

Sharifnia, T., Wawer, M.J., Chen, T., Huang, Q.-., Weir, B.A., Sizemore, A., Lawlor, M.A., Goodale, A., Cowley, G.S., Vazquez, F., et al. (2019). Small-molecule targeting of brachyury transcription factor addiction in chordoma. Nature medicine, Vol.25 (2), pp. 292-300.

Calpena, E., Hervieu, A., Kaserer, T., Swagemakers, S.M., Goos, J.A., Popoola, O., Ortiz-Ruiz, M.J., Barbaro-Dieber, T., Bownass, L., Brilstra, E.H., et al. (2019). De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder. The american journal of human genetics, Vol.104 (4), pp. 709-720.

Clarke, P.A., Roe, T., Swabey, K., Hobbs, S.M., McAndrew, C., Tomlin, K., Westwood, I., Burke, R., van Montfort, R. & Workman, P., et al. (2019). Dissecting mechanisms of resistance to targeted drug combination therapy in human colorectal cancer. Oncogene, Vol.38 (25), pp. 5076-5090.

Lampis, A., Carotenuto, P., Vlachogiannis, G., Cascione, L., Hedayat, S., Burke, R., Clarke, P., Bosma, E., Simbolo, M., Scarpa, A., et al. (2018). MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology, Vol.154 (4), pp. 1066-1079.e5.

Bright, M.D., Clarke, P.A., Workman, P. & Davies, F.E. (2018). Oncogenic RAC1 and NRAS drive resistance to endoplasmic reticulum stress through MEK/ERK signalling. Cellular signalling, Vol.44, pp. 127-137.

Pawlyn, C., Bright, M.D., Buros, A.F., Stein, C.K., Walters, Z., Aronson, L.I., Mirabella, F., Jones, J.R., Kaiser, M.F., Walker, B.A., et al. (2017). Overexpression of EZH2 in multiple myeloma is associated with poor prognosis and dysregulation of cell cycle control. Blood cancer journal, Vol.7 (3), pp. e549-e549.

Whittaker, S.R., Mallinger, A., Workman, P. & Clarke, P.A. (2017). Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol ther, Vol.173, pp. 83-105.  show abstract

Agliano, A., Balarajah, G., Ciobota, D.M., Sidhu, J., Clarke, P.A., Jones, C., Workman, P., Leach, M.O. & Al-Saffar, N.M. (2017). Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy. Oncotarget, Vol.8 (29).

Vaughan, L., Clarke, P.A., Barker, K., Chanthery, Y., Gustafson, C.W., Tucker, E., Renshaw, J., Raynaud, F., Li, X., Burke, R., et al. (2016). Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget, Vol.7 (36).

Mallinger, A., Schiemann, K., Rink, C., Sejberg, J., Honey, M.A., Czodrowski, P., Stubbs, M., Poeschke, O., Busch, M., Schneider, R., et al. (2016). 2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19. Acs medicinal chemistry letters, Vol.7 (6), pp. 573-578.

Mallinger, A., Schiemann, K., Rink, C., Stieber, F., Calderini, M., Crumpler, S., Stubbs, M., Adeniji-Popoola, O., Poeschke, O., Busch, M., et al. (2016). Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19. Journal of medicinal chemistry, Vol.59 (3), pp. 1078-1101.

Workman, P., Clarke, P.A. & Al-Lazikani, B. (2016). Blocking the survival of the nastiest by HSP90 inhibition. Oncotarget, Vol.7 (4).

Czodrowski, P., Mallinger, A., Wienke, D., Esdar, C., Pöschke, O., Busch, M., Rohdich, F., Eccles, S.A., Ortiz-Ruiz, M.-., Schneider, R., et al. (2016). Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening. J med chem, Vol.59 (20), pp. 9337-9349.  show abstract

Sarker, D., Ang, J.E., Baird, R., Kristeleit, R., Shah, K., Moreno, V., Clarke, P.A., Raynaud, F.I., Levy, G., Ware, J.A., et al. (2015). First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin cancer res, Vol.21 (1), pp. 77-86.  show abstract

Smith, J.R., de Billy, E., Hobbs, S., Powers, M., Prodromou, C., Pearl, L., Clarke, P.A. & Workman, P. (2015). Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene, Vol.34 (1), pp. 15-26.  show abstract

Smith, J.R., de Billy, E., Hobbs, S., Powers, M., Prodromou, C., Pearl, L., Clarke, P.A. & Worknnan, P. (2015). Restricting direct interaction of CDC37 with HSP90 does not compromise chaperoning of client proteins. Oncogene, Vol.34 (1), pp. 15-26.

Yap, T.A., Bjerke, L., Clarke, P.A. & Workman, P. (2015). Drugging PI3K in cancer: refining targets and therapeutic strategies. Current opinion in pharmacology, Vol.23, pp. 98-107.

Dale, T., Clarke, P.A., Esdar, C., Waalboer, D., Adeniji-Popoola, O., Ortiz-Ruiz, M.-., Mallinger, A., Samant, R.S., Czodrowski, P., Musil, D., et al. (2015). A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease. Nature chemical biology, Vol.11 (12), pp. 973-980.

Mallinger, A., Crumpler, S., Pichowicz, M., Waalboer, D., Stubbs, M., Adeniji-Popoola, O., Wood, B., Smith, E., Thai, C., Henley, A.T., et al. (2015). Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. J med chem, Vol.58 (4), pp. 1717-1735.  show abstract

Samant, R.S., Clarke, P.A. & Workman, P. (2014). E3 ubiquitin ligase Cullin-5 modulates multiple molecular and cellular responses to heat shock protein 90 inhibition in human cancer cells. Proc natl acad sci u s a, Vol.111 (18), pp. 6834-6839.  show abstract

Al-Saffar, N.M., Marshall, L.V., Jackson, L.E., Balarajah, G., Eykyn, T.R., Agliano, A., Clarke, P.A., Jones, C., Workman, P., Pearson, A.D., et al. (2014). Lactate and choline metabolites detected in vitro by nuclear magnetic resonance spectroscopy are potential metabolic biomarkers for PI3K inhibition in pediatric glioblastoma. Plos one, Vol.9 (8), p. e103835.  show abstract

Gonzalez de Castro, D., Clarke, P.A., Al-Lazikani, B. & Workman, P. (2013). Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin pharmacol ther, Vol.93 (3), pp. 252-259.  show abstract

Polier, S., Samant, R.S., Clarke, P.A., Workman, P., Prodromou, C. & Pearl, L.H. (2013). ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nat chem biol, Vol.9 (5), pp. 307-312.  show abstract

Polier, S., Samant, R.S., Clarke, P.A., Workman, P., Prodromou, C. & Pearl, L.H. (2013). Erratum: Corrigendum: ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system. Nature chemical biology, Vol.9 (6), pp. 406-406.

Workman, P., Al-Lazikani, B. & Clarke, P.A. (2013). Genome-based cancer therapeutics: targets, kinase drug resistance and future strategies for precision oncology. Curr opin pharmacol, Vol.13 (4), pp. 486-496.  show abstract

Saturno, G., Valenti, M., De Haven Brandon, A., Thomas, G.V., Eccles, S., Clarke, P.A. & Workman, P. (2013). Combining trail with PI3 kinase or HSP90 inhibitors enhances apoptosis in colorectal cancer cells via suppression of survival signaling. Oncotarget, Vol.4 (8), pp. 1185-1198.  show abstract

Powers, M.V., Valenti, M., Miranda, S., Maloney, A., Eccles, S.A., Thomas, G., Clarke, P.A. & Workman, P. (2013). Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget, Vol.4 (11), pp. 1963-1975.  show abstract

de Billy, E., Clarke, P.A. & Workman, P. (2013). HSF1 in Translation. Cancer cell, Vol.24 (2), pp. 147-149.  show abstract

Couty, S., Westwood, I.M., Kalusa, A., Cano, C., Travers, J., Boxall, K., Chow, C.L., Burns, S., Schmitt, J., Pickard, L., et al. (2013). The discovery of potent ribosomal S6 kinase inhibitors by high-throughput screening and structure-guided drug design. Oncotarget, Vol.4, pp. 1-15.  show abstract

Samant, R.S., Clarke, P.A. & Workman, P. (2012). The expanding proteome of the molecular chaperone HSP90. Cell cycle, Vol.11 (7), pp. 1301-1308.  show abstract

Hoelder, S., Clarke, P.A. & Workman, P. (2012). Discovery of small molecule cancer drugs: successes, challenges and opportunities. Mol oncol, Vol.6 (2), pp. 155-176.  show abstract

Pintzas, A., Zhivotovsky, B., Workman, P., Clarke, P.A., Linardopoulos, S., Martinou, J.-., Lacal, J.C., Robine, S., Nasioulas, G. & Andera, L., et al. (2012). Sensitization of (colon) cancer cells to death receptor related therapies: a report from the FP6-ONCODEATH research consortium. Cancer biol ther, Vol.13 (7), pp. 458-466.  show abstract

Carden, C.P., Stewart, A., Thavasu, P., Kipps, E., Pope, L., Crespo, M., Miranda, S., Attard, G., Garrett, M.D., Clarke, P.A., et al. (2012). The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer. Mol cancer ther, Vol.11 (7), pp. 1609-1617.  show abstract

Workman, P., Clarke, P.A. & Al-Lazikani, B. (2012). Personalized medicine: patient-predictive panel power. Cancer cell, Vol.21 (4), pp. 455-458.  show abstract

Clarke, P.A. & Workman, P. (2012). Phosphatidylinositide-3-kinase inhibitors: addressing questions of isoform selectivity and pharmacodynamic/predictive biomarkers in early clinical trials. J clin oncol, Vol.30 (3), pp. 331-333.

Workman, P. & Clarke, P. (2012). PI3 Kinase in Cancer: From Biology to Clinic. Am soc clin oncol educ book, , pp. e93-e98.  show abstract

Shuttleworth, S.J., Silva, F.A., Cecil, A.R., Tomassi, C.D., Hill, T.J., Raynaud, F.I., Clarke, P.A. & Workman, P. (2011). Progress in the preclinical discovery and clinical development of class I and dual class I/IV phosphoinositide 3-kinase (PI3K) inhibitors. Current medicinal chemistry, Vol.18 (18), pp. 2686-2714.  show abstract  full text

Rao, S., Welsh, L., Cunningham, D., Te-Poele, R.H., Benson, M., Norman, A., Saffery, C., Giddings, I., Workman, P. & Clarke, P.A., et al. (2011). Correlation of Overall Survival With Gene Expression Profiles in a Prospective Study of Resectable Esophageal Cancer. Clin colorectal canc, Vol.10 (1), pp. 48-56.  show abstract

Workman, P. & Clarke, P.A. (2011). Resisting Targeted Therapy: Fifty Ways to Leave Your EGFR. Cancer cell, Vol.19 (4), pp. 437-440.  show abstract

Large, J.M., Torr, J.E., Raynaud, F.I., Clarke, P.A., Hayes, A., Stefano, F.D., Urban, F., Shuttleworth, S.J., Saghir, N., Sheldrake, P., et al. (2011). Preparation and evaluation of trisubstituted pyrimidines as phosphatidylinositol 3-kinase inhibitors 3-Hydroxyphenol analogues and bioisosteric replacements. Bioorg med chem, Vol.19 (2), pp. 836-851.  show abstract

Bahn, J.D., Skipper, J., Garcia, A., Jiang, P., Osgood, R., Symons, R., Frost, G.I., Shepard, H., Thompson, C.B. & Li, X., et al. (2011). Abstract 2501: PEGylated human recombinant hyaluronidase (PEGPH20) enhances radiotherapy in hyaluronan-rich solid tumors. Tumor biology, .

Shuttleworth, S.J., Silva, F.A., Cecil, A.R., Tomassi, C.D., Hill, T.J., Raynaud, F.I., Clarke, P.A. & Workman, P. (2011). Progress in the Preclinical Discovery and Clinical Development of Class I and Dual Class I/IV Phosphoinositide 3-Kinase (PI3K) Inhibitors. Curr med chem, .  show abstract

Al-Saffar, N.M., Jackson, L.E., Raynaud, F.I., Clarke, P.A., Ramírez de Molina, A., Lacal, J.C., Workman, P. & Leach, M.O. (2010). The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer res, Vol.70 (13), pp. 5507-5517.  show abstract

Workman, P., Clarke, P.A., Raynaud, F.I. & van Montfort, R.L. (2010). Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer res, Vol.70 (6), pp. 2146-2157.  show abstract

Guillard, S., Clarke, P.A., Te Poele, R., Mohri, Z., Bjerke, L., Valenti, M., Raynaud, F., Eccles, S.A. & Workman, P. (2009). Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell cycle, Vol.8 (3), pp. 443-453.  show abstract

Baird, R.D., Kitzen, J., Clarke, P.A., Planting, A., Reade, S., Reid, A., Welsh, L., López Lázaro, L., de las Heras, B., Judson, I.R., et al. (2009). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent, administered to adult patients with advanced solid tumors. Mol cancer ther, Vol.8 (6), pp. 1430-1437.  show abstract

Raynaud, F.I., Eccles, S.A., Patel, S., Alix, S., Box, G., Chuckowree, I., Folkes, A., Gowan, S., De Haven Brandon, A., Di Stefano, F., et al. (2009). Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol cancer ther, Vol.8 (7), pp. 1725-1738.  show abstract

Powers, M.V., Clarke, P.A. & Workman, P. (2009). Death by chaperone HSP90, HSP70 or both?. Cell cycle, Vol.8 (4), pp. 518-526.  show abstract

Smith, J.R., Clarke, P.A., de Billy, E. & Workman, P. (2009). Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors. Oncogene, Vol.28 (2), pp. 157-169.  show abstract

Powers, M.V., Clarke, P.A. & Workman, P. (2008). Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer cell, Vol.14 (3), pp. 250-262.  show abstract

Vaughan, C.K., Mollapour, M., Smith, J.R., Truman, A., Hu, B., Good, V.M., Panaretou, B., Neckers, L., Clarke, P.A., Workman, P., et al. (2008). Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol cell, Vol.31 (6), pp. 886-895.  show abstract

Maloney, A., Clarke, P.A., Naaby-Hansen, S., Stein, R., Koopman, J.-., Akpan, A., Yang, A., Zvelebil, M., Cramer, R., Stimson, L., et al. (2007). Gene and protein expression profiling of human ovarian cancer cells treated with the heat shock protein 90 inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer res, Vol.67 (7), pp. 3239-3253.  show abstract

Sharp, S.Y., Boxall, K., Rowlands, M., Prodromou, C., Roe, S.M., Maloney, A., Powers, M., Clarke, P.A., Box, G., Sanderson, S., et al. (2007). In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer res, Vol.67 (5), pp. 2206-2216.  show abstract

Clarke, P.A., Guillard, S., Di Stefano, F., Poele, R.T., Valenti, M., Brandon, A.D., Eccles, S., Raynaud, F. & Workman, P. (2007). Characterization of a potent inhibitor of class 1 phosphatidylinositide-3 '-kinases (PI3K) in human glioma. Mol cancer ther, Vol.6 (12), pp. 3414S-3414S.

Baird, R., Planting, A., Reid, A., Kitzen, J., Reade, S., Clarke, P., Welsh, L., Lazaro, L.L., Heras, B.D., Judson, I., et al. (2007). Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors. Mol cancer ther, Vol.6 (12), pp. 3381S-3381S.

Raynaud, F.I., Eccles, S., Clarke, P.A., Hayes, A., Nutley, B., Alix, S., Henley, A., Di-Stefano, F., Ahmad, Z., Guillard, S., et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer res, Vol.67 (12), pp. 5840-5850.  show abstract

Raynaud, F., Eccles, S., Clarke, P., Hayes, A., Di Stefano, F., Ahmad, Z., Guillard, S., Patel, S. & Workman, P. (2006). In vitro and in vivo pharmacological properties of the potent phosphatidylinositol 3-kinase (PI3K) family inhibitor PI103. Ejc suppl, Vol.4 (12), pp. 172-172.

Workman, P. & Clarke, P.A. (2006). Hot off the press: Global gene expression signatures for global chemical probe and drug discovery. Mol biosyst, Vol.2, pp. 605-608.

Hardcastle, A., Boxall, K., Richards, J., Tomlin, P., Sharp, S., Clarke, P., Workman, P. & Aherne, W. (2005). Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90. Assay drug dev technol, Vol.3 (3), pp. 273-285.  show abstract

Clarke, P.A., te Poele, R. & Workman, P. (2004). Gene expression microarray technologies in the development of new therapeutic agents. Eur j cancer, Vol.40 (17), pp. 2560-2591.  show abstract

Clarke, P.A., Pestell, K.E., Di Stefano, F., Workman, P. & Walton, M.I. (2004). Characterisation of molecular events following cisplatin treatment of two curable ovarian cancer models: contrasting role for p53 induction and apoptosis in vivo. Br j cancer, Vol.91 (8), pp. 1614-1623.  show abstract

Andreyev, H.J., Benamouzig, R., Beranek, M., Clarke, P., Cunningham, D., Norman, A.R., Giaretti, W., de Goeij, A.F., Iacopetta, B.J., Jullian, E., et al. (2003). Mutant K-ras2 in serum. Gut, Vol.52 (6), pp. 915-916.

Maloney, A., Clarke, P.A. & Workman, P. (2003). Genes and proteins governing the cellular sensitivity to HSP90 inhibitors: a mechanistic perspective. Curr cancer drug targets, Vol.3 (5), pp. 331-341.  show abstract

Clarke, P.A., George, M.L., Easdale, S., Cunningham, D., Swift, R.I., Hill, M.E., Tait, D.M. & Workman, P. (2003). Molecular pharmacology of cancer therapy in human colorectal cancer by gene expression profiling. Cancer res, Vol.63 (20), pp. 6855-6863.  show abstract

Aherne, W., Maloney, A., Prodromou, C., Rowlands, M.G., Hardcastle, A., Boxall, K., Clarke, P., Walton, M.I., Pearl, L. & Workman, P., et al. (2003). Assays for HSP90 and inhibitors. Methods mol med, Vol.85, pp. 149-161.

Easdale, S., Clarke, P., Titley, J., Wooster, R. & Workman, P. (2002). Gene expression and cell cycle analysis of colorectal cancer cell lines exposed to 5FU and 5FDURD. Brit j cancer, Vol.86, pp. S49-S49.

Panaretou, B., Siligardi, G., Meyer, P., Maloney, A., Sullivan, J.K., Singh, S., Millson, S.H., Clarke, P.A., Naaby-Hansen, S., Stein, R., et al. (2002). Activation of the ATPase activity of hsp90 by the stress-regulated cochaperone aha1. Mol cell, Vol.10 (6), pp. 1307-1318.  show abstract

Al-Saffar, N.M., Titley, J.C., Robertson, D., Clarke, P.A., Jackson, L.E., Leach, M.O. & Ronen, S.M. (2002). Apoptosis is associated with triacylglycerol accumulation in Jurkat T-cells. Br j cancer, Vol.86 (6), pp. 963-970.  show abstract

Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J., Dix, B.R., Iacopetta, B.J., Young, J., Walsh, T., Ward, R., Hawkins, N., et al. (2001). Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. British journal of cancer, Vol.85 (5), pp. 692-696.

Andreyev, H.J., Ross, P.J., Cunningham, D. & Clarke, P.A. (2001). Antisense treatment directed against mutated Ki-ras in human colorectal adenocarcinoma. Gut, Vol.48 (2), pp. 230-237.  show abstract

Workman, P. & Clarke, P.A. (2001). Innovative cancer drug targets: genomics, transcriptomics and clinomics. Expert opin pharmacother, Vol.2 (6), pp. 911-915.

Ross, P.J., George, M., Cunningham, D., DiStefano, F., Andreyev, H.J., Workman, P. & Clarke, P.A. (2001). Inhibition of Kirsten-ras expression in human colorectal cancer using rationally selected Kirsten-ras antisense oligonucleotides. Mol cancer ther, Vol.1 (1), pp. 29-41.  show abstract

Kelland, L.R., Smith, V., Valenti, M., Patterson, L., Clarke, P.A., Detre, S., End, D., Howes, A.J., Dowsett, M., Workman, P., et al. (2001). Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer. Clin cancer res, Vol.7 (11), pp. 3544-3550.  show abstract

Clarke, P.A., te Poele, R., Wooster, R. & Workman, P. (2001). Gene expression microarray analysis in cancer biology, pharmacology, and drug development: progress and potential. Biochem pharmacol, Vol.62 (10), pp. 1311-1336.  show abstract

Hostein, I., Robertson, D., DiStefano, F., Workman, P. & Clarke, P.A. (2001). Inhibition of signal transduction by the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin results in cytostasis and apoptosis. Cancer res, Vol.61 (10), pp. 4003-4009.  show abstract

Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., Raynaud, F., di Stefano, F. & Cotter, F.E. (2000). Phase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J clin oncol, Vol.18 (9), pp. 1812-1823.  show abstract

Ross, P.J., Andreyev, H.J., George, M., di Stefano, F., Cunningham, D. & Clarke, P.A. (2000). Rational selection of antisense Kirsten ras oligonucleotide by mapping accessible sites with ribonuclease H. British journal of cancer, Vol.83, pp. 13-13.

Maloney, A., Clarke, P.A., Walton, M.I., Prodromou, C., Pearl, L., Sharp, S., Kelland, L. & Workman, P. (2000). Gene expression profiling of HT29 colon carcinoma cells after treatment with analogues of the Hsp90 inhibitor 17-allylamino-17-demethoxy-geldanamycin (17AAG) and the structurally dissimilar compound radicicol. Clin cancer res, Vol.6, pp. 4532S-4532S.

Clarke, P.A., Hostein, I., Banerji, U., Stefano, F.D., Maloney, A., Walton, M., Judson, I. & Workman, P. (2000). Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene, Vol.19 (36), pp. 4125-4133.  show abstract

Ronen, S.M., DiStefano, F., McCoy, C.L., Robertson, D., Smith, T.A., Al-Saffar, N.M., Titley, J., Cunningham, D.C., Griffiths, J.R., Leach, M.O., et al. (1999). Magnetic resonance detects metabolic changes associated with chemotherapy-induced apoptosis. Br j cancer, Vol.80 (7), pp. 1035-1041.  show abstract

Waters, J.S., Webb, A., Cunningham, D., Clarke, P.A., di Stefano, F., Raynaud, F., Brown, B.D. & Cotter, F. (1999). Results of a phase 1 clinical trial of BCL-2 antisense molecule G3139 (Genta) in patients with non-Hodgkin's lymphoma (NHL). Brit j cancer, Vol.80, pp. 62-62.

Clarke, P.A. (1999). Labeling and purification of RNA synthesized by in vitro transcription. Methods mol biol, Vol.118, pp. 1-10.

Clarke, P.A. (1999). RNA footprinting and modification interference analysis. Methods mol biol, Vol.118, pp. 73-91.

Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J.R. & Clarke, P.A. (1998). Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J natl cancer inst, Vol.90 (9), pp. 675-684.  show abstract

Tilsed, J.V., Andreyev, H.J., Cunningham, D. & Clarke, P.A. (1998). ras pathways in colorectal cancer. British journal of surgery, Vol.85, pp. 83-83.

Andreyev, H.J., Ross, P.J., Cunningham, D. & Clarke, P.A. (1997). Effective targeting of colorectal cancer Kirsten ras point mutations with antisense therapy in-vitro. Gut, Vol.40, pp. TH178-TH178.

Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J. & Clarke, P.A. (1997). Kirsten ras mutations in 2,667 patients with colorectal cancer: Results of the rascal (ras collaborative) project. Gut, Vol.40, pp. TH193-TH193.

Andreyev, H.J., Norman, A.R., Cunningham, D., Oates, J. & Clarke, P.A. (1997). Kirsten ras mutations in 2,667 patients with colorectal cancer: Results of the RASCAL (ras collaborative) project. Gastroenterology, Vol.112 (4), pp. A532-A532.

Andreyev, H.J., Ross, P.J., Cunningham, D. & Clarke, P.A. (1997). Effective targeting of colorectal cancer Kirsten ras point mutations with antisense therapy in-vitro. Gastroenterology, Vol.112 (4), pp. A532-A532.

Circle, D.A., Neel, O.D., Robertson, H.D., Clarke, P.A. & Mathews, M.B. (1997). Surprising specificity of PKR binding to delta agent genomic RNA. Rna, Vol.3 (4), pp. 438-448.

Webb, A., Cunningham, D., Cotter, F., Ross, P., Walters, J., Judson, I., Raynaud, F., Clarke, P. & Dziewanowska, Z.E. (1997). First demonstration of anti-lymphoma activity of BCL-2 antisense molecule-G3139; Results of phase I/IIA clinical trial. Eur j cancer, Vol.33, pp. 1180-1180.

Andreyev, H.J., Tilsed, J.V., Cunningham, D., Sampson, S.A., Norman, A.R., Schneider, H.J. & Clarke, P.A. (1997). K-ras mutations in patients with early colorectal cancers. Gut, Vol.41 (3), pp. 323-329.  show abstract

Cotter, F., Webb, A., Cunningham, D., Fennell, D., Corbo, M., Ross, P., Walters, J., Judson, I., Raynaud, F., Clarke, P., et al. (1997). Activity of BCL-2 antisense molecule G3139 against, lymphoma/leukemia; Results from a phase I/IIA clinical trial and further developments. Blood, Vol.90 (10), pp. 2289-2289.

Webb, A., Cunningham, D., Cotter, F., Clarke, P.A., di Stefano, F., Ross, P., Corbo, M. & Dziewanowska, Z. (1997). BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, Vol.349 (9059), pp. 1137-1141.  show abstract

Schneider, H.J., Sampson, S.A., Cunningham, D., Norman, A.R., Andreyev, H.J., Tilsed, J.V. & Clarke, P.A. (1997). Bcl-2 expression and response to chemotherapy in colorectal adenocarcinomas. Br j cancer, Vol.75 (3), pp. 427-431.  show abstract

Hill, M.E., MacLennan, K.A., Cunningham, D.C., Vaughan Hudson, B., Burke, M., Clarke, P., Di Stefano, F., Anderson, L., Vaughan Hudson, G., Mason, D., et al. (1996). Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Blood, Vol.88 (3), pp. 1046-1051.  show abstract

Corbo, M., Hill, M., Pocock, C., Clarke, P., Malone, M., Cunningham, D. & Cotter, F. (1996). In vivo engraftment and BCL-2 antisense treatment of low grade B-cell lymphoma lymph node biopsies in SCID mice. British journal of haematology, Vol.93, pp. 214-214.

Andreyev, H.J., Tilsed, J.V., Cunningham, D., Sampson, S.A., Norman, A.R., Schneider, H.J. & Clarke, P. (1996). Mutations in codons 12 & 13 of the Kirsten-ras gene are not related to relapse in patients with early colorectal cancers. Gastroenterology, Vol.110 (4), pp. A484-A484.

Tilsed, J.V., Andreyev, H.J., Cunningham, D., Norman, A.R., Schneider, H.J., Sampson, S.A. & Clarke, P. (1996). CD44v6 expression does not predict outcome in early colorectal cancer. Gastroenterology, Vol.110 (4), pp. A603-A603.

Clarke, P.A., Schneider, H.J., Cunningham, D., Norman, A.R., Sampson, S.A., Tilsed, J.V. & Andreyev, H.J. (1996). Bcl-2 expression does not influence response to chemotherapy in colorectal cancer. Gastroenterology, Vol.110 (4), pp. A504-A504.

CLARKE, P.A. & MATHEWS, M.B. (1995). INTERACTIONS BETWEEN THE DOUBLE-STRANDED-RNA BINDING MOTIF AND RNA - DEFINITION OF THE BINDING-SITE FOR THE INTERFERON-INDUCED PROTEIN-KINASE DAI (PKR) ON ADENOVIRUS VA RNA. Rna, Vol.1 (1), pp. 7-20.

CLARKE, P., HICKISH, T., ROBERTSON, D., HILL, M., DISTEFANO, F. & CONNINGHAM, D. (1994). IN-VIVO EXPRESSION AND LOCALIZATION OF BHRF-1, AN EPSTEIN-BARR-VIRUS (EBV) ENCODED BCL-2 HOMOLOG. Journal of cellular biochemistry, , pp. 230-230.

Hickish, T., Robertson, D., Clarke, P., Hill, M., di Stefano, F., Clarke, C. & Cunningham, D. (1994). Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2. Cancer res, Vol.54 (10), pp. 2808-2811.  show abstract

Clarke, P.A., Sharp, N.A. & Clemens, M.J. (1992). Expression of genes for the Epstein--Barr virus small RNAs EBER-1 and EBER-2 in Daudi Burkitt's lymphoma cells: effects of interferon treatment. Journal of general virology, Vol.73 (12), pp. 3169-3175.

Clarke, P.A., Schwemmle, M., Schickinger, J., Hilse, K. & Clemens, M.J. (1991). Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic acids research, Vol.19 (2), pp. 243-248.

Clarke, P.A., Sharp, N.A., Arrand, J.R. & Clemens, M.J. (1990). Epstein-Barr virus gene expression in interferon-treated cells. Biochimica et biophysica acta (bba) - gene structure and expression, Vol.1050 (1-3), pp. 167-173.

CLARKE, P.A., SHARP, N.A. & CLEMENS, M.J. (1990). Translational control by the Epstein-Barr virus small RNA EBER-1 Reversal of the double-stranded RNA-induced inhibition of protein synthesis in reticulocyte lysates. European journal of biochemistry, Vol.193 (3), pp. 635-641.

CLARKE, P.A., SHARP, N.A., ARRAND, J.R. & CLEMENS, M.J. (1990). EPSTEIN-BARR-VIRUS GENE-EXPRESSION IN INTERFERON-TREATED CELLS - IMPLICATIONS FOR THE REGULATION OF PROTEIN-SYNTHESIS AND THE ANTIVIRAL STATE. Biochimica et biophysica acta, Vol.1050 (1-3), pp. 167-173.

Workman, P., Clarke, P.A., Guillard, S. & Raynaud, F.I. Drugging the PI3 kinome. Nat biotechnol., Vol.24 (7), pp. 794-3.

Folkes, A.J., Ahmadi, K., Alderton, W.K., Alix, S., Baker, S.J., Box, G., Chuckowree, I.S., Clarke, P.A., Depledge, P., Eccles, S.A., et al. The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor of class I PI3 kinase for the treatment of cancer. J med chem, Vol.51 (18), pp. 5522-10.  show abstract

Clarke, P.A., Ortiz-Ruiz, M.-., TePoele, R., Adeniji-Popoola, O., Box, G., Court, W., Czasch, S., El Bawab, S., Esdar, C., Ewan, K., et al. Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases. Elife, Vol.5.  show abstract

Linardopoulos, S., dolly, S., gurden, M., drosopoulos, K., clarke, P., bono, J., kaye, S. & workman, P. RNAi screen reveals synthetic lethality between Cyclin G-associated kinase and FBXW7 by inducing aberrant mitoses. British journal of cancer, .

Al-Saffar, N.M., Agliano, A., Marshall, L.V., Jackson, L.E., Balarajah, G., Sidhu, J., Clarke, P.A., Jones, C., Workman, P., Pearson, A.D., et al. In vitro nuclear magnetic resonance spectroscopy metabolic biomarkers for the combination of temozolomide with PI3K inhibition in paediatric glioblastoma cells. Plos one, Vol.12 (7), pp. e0180263-e0180263.

Whittaker, S.R., Barlow, C., Martin, M.P., Mancusi, C., Wagner, S., Self, A., Barrie, E., te Poele, R., Sharp, S., Brown, N., et al. Molecular profiling and combinatorial activity of CCT068127: A potent CDK2 and CDK9 inhibitor. Mol oncol, , pp. n/a-n/a.

Poon, E., Jamin, Y., Liang, T., Waltz, S., Kwok, C., Hakkert, A., Richards, M., Urban, Z., Thway, K., Zied, R., et al. Pharmacological blockade of MYCN in neuroblastoma using orally-bioavailable CDK inhibitors reveals an approach widely applicable to Myc-dependent cancers. Nature medicine, .  show abstract

Cheeseman, M., Chessum, N., Sharp, S., Caldwell, J., Pasqua, E., Wilding, B., Colombano, G., Collins, I., Ozer, B., Richards, M., et al. Demonstrating In-Cell Target Engagement using a Pirin Protein Degradation Probe (CCT367766). Journal of medicinal chemistry, .  show abstract

Vlachogiannis, G., Hedayat, S., Vatsiou, A., Jamin, Y., Fernandez Mateos, J., Khan, K., Lampis, A., Eason, K., Burke, R., Rata, M., et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, .

Antolin, A.A., Ameratunga, M., Banerji, U., Clarke, P., Workman, P. & Al-Lazikani, B. The off-target kinase landscape of clinical PARP inhibitors. , .  show abstract


Book Chapters

te Poele, R., Clarke, P.A. & Workman, P. (2004). Gene microarray technologies for cancer drug discovery and development. In Prendergast, G.C. (Ed.), Molecular Cancer Therapeutics: Strategies for Drug Discovery and Development. 2nd ed. (pp. 142-182). New Jersey, Wiley-Liss Hoboken.


Conferences

Clarke, P.A., Roe, T., Swabey, K., McAndrew, C., Boxall, K., Westwood, I., van Montfort, R., Al-Lazikhani, B. & Workman, P. (2015). Abstract 2843: Resistance to ERK inhibitors as a result of an acquired novel P-loop mutation of ERK2, Presented at Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA, Experimental and Molecular Therapeutics, .

Howes, J., Lu, B.-., Powers, M., Mitsopoulos, C., Al-Lazikani, B., Linardopoulos, S., Clarke, P. & Workman, P. (2014). Abstract 2730: RNAi knockdown or chemical inhibition of anaphase-promoting complex components is synthetic lethal with HSP90 inhibition, Presented at Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Experimental and Molecular Therapeutics, .

Clarke, P.A., Roe, T. & Workman, P. (2014). Abstract 2925: Mechanism-based combinatorial treatment of KRAS mutant colorectal cancer with MEK and PI3K pathway inhibitors, Presented at Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA, Experimental and Molecular Therapeutics, .

Nandhabalan, M., Bjerke, L., Vinci, M., Burford, A., Ingram, W., Mackay, A., von Bueren, A., Baudis, M., Clarke, P., Collins, I., et al. (2014). TARGETING MYC/MYCN BY INHIBITION OF CHECKPOINT KINASE 1 (CHK1) SENSITIZES PAEDIATRIC GLIOBLASTOMA (PGBM) CELLS TO TEMOZOLOMIDE, NEURO-ONCOLOGY, Vol.16, p.49.

Howes, J., Lu, B.-., Powers, M., Clarke, P. & Workman, P. (2013). Synthetic lethal screen identifies candidates that modulate cancer cell sensitivity in response to HSP90 inhibition., CANCER RESEARCH, Vol.73 (8).

Clarke, P.A., Welsh, L., Valenti, M., Eccles, S. & Workman, P. (2008). Hsp90 inhibitors target addiction to mutant oncoproteins in colorectal cancer, Presented at 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Geneva, SWITZERLAND. EJC SUPPLEMENTS, Vol.6 (12), p.47.

Raynaud, F., Eccles, S., Clarke, P., Hayes, A., Di-Stefano, F., Ahmed, Z., Guillard, S. & Workman, P. (2007). Pharmacological properties of a potent inhibitor of the phosphatidylinositol 3-kinase (PI3k) family, Presented at 5th International Symposium onTargeted Anticancer Therapies, Amsterdam, NETHERLANDS. ANNALS OF ONCOLOGY, Vol.18, p.23.

Powers, M.V., Clarke, P.A. & Wokman, P. (2006). Targeting the two major isoforms of heat shock protein 70: A novel approach to inhibiting the molecular chaperone heat shock protein 90, CANCER RESEARCH, Vol.66 (8).

Clarke, P.A., George, M.L., Easdale, S., Cunningham, D., Swift, I., Hill, M.E., Tait, D.M. & Workman, P. (2003). Molecular pharmacology of cancer therapy inhuman colorectal cancer by microarray gene expression profiling., Presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, BOSTON, MASSACHUSETTS. CLINICAL CANCER RESEARCH, Vol.9 (16), p.6122S.

Clarke, P.A., Maloney, A., Naaby-Hansen, S., Claus, R., Stein, R., Yang, A., Akpan, A., Walton, M.I., Waterfield, M. & Workman, P., et al. (2002). Gene expression microarray and 2D proteomic profiling of human ovarian adenocarcinoma cells following treatment with 17AAG, an inhibitor of the molecular chaperone Hsp90, Presented at 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT, GERMANY. EUROPEAN JOURNAL OF CANCER, Vol.38, pp.S92-S93.

Easdale, S., Clarke, P., Titley, J., Cattini, N., Wooster, R. & Workman, P. (2002). Gene expression profiling of colorectal cancer cell lines exposed to 5-fluorouracil (5-FU) and 5-FdUrd, Presented at 14th EORTC/NCI/AACR Symposium on Molecular Targets and Cancer Therapeutics, FRANKFURT, GERMANY. EUROPEAN JOURNAL OF CANCER, Vol.38, pp.S21-S22.

In this section

Publications